论文部分内容阅读
目的探讨分析膀胱内灌注吡柔比星(THP)与丝裂霉素C(MMC)在预防浅表性膀胱癌术后复发上的疗效。方法随机选择2006年～2010年在本院泌尿外科手术治疗的140例浅表性膀胱癌患者,按照随机对照的原则分为吡柔比星组(TH组,n=70)及丝裂霉素组(MMC组,n=70),分别进行膀胱内灌注化疗,随访2年,观察肿瘤术后复发情况。结果丝裂霉素组患者的复发率高于吡柔比星,差异有统计学意义(P<0.05)。结论吡柔比星的疗效优于丝裂霉素,副作用较少。
Objective To investigate the efficacy of intravesical instillation of pirarubicin (THP) and mitomycin C (MMC) in the prevention of postoperative recurrence of superficial bladder cancer. Methods A total of 140 patients with superficial bladder cancer who underwent urologic surgery in our hospital from 2006 to 2010 were randomly divided into two groups according to randomized control: pirarubicin (TH group, n = 70) and mitomycin Group (MMC group, n = 70) were intravesical chemotherapy, followed up for 2 years to observe the recurrence of the tumor. Results The recurrence rate of mitomycin group was higher than that of pirarubicin, the difference was statistically significant (P <0.05). Conclusion Pirarubicin is superior to mitomycin with fewer side effects.